Topical three-drug combination in the management of pseudophakic cystoid macular edema

Author:

Sane Siddharth1,Mahalingam Prabhushanker1,Ganesan Geetha1

Affiliation:

1. Department of Cataract and Vitreoretinal Services, Sankara Eye Hospital, Coimbatore, Tamil Nadu, India

Abstract

The purpose was to report the outcome after usage of three topical eyedrops combination, consisting of one steroid, one carbonic anhydrase inhibitor (CAI), and one non-steroidal anti-inflammatory drug (NSAID) in the treatment of pseudophakic cystoid macula edema (PCME) or Irvine–Gass syndrome. Treatment response monitoring of two patients with PCME to the combination of three eyedrops in a fixed dose regimen done using Optical Coherence Tomography. In both cases, significant improvement was documented within 1 week of starting the treatment, with respect to both visual acuity as well as central macular thickness and intraretinal fluid or cystoid macula edema (CME) resolution. The combination of three topical drugs of difluprednate (steroid), dorzolamide (CAI), and nepafenac (NSAID) is highly effective in treating select cases of pseudophakic CME and negates the need for usage of intravitreal (IVT) or posterior sub-Tenon’s injection of drugs such as triamcinolone acetonide, i.e., IVT triamcinolone acetonide, or posterior subtenon thus avoiding its associated complications.

Publisher

Medknow

Reference12 articles.

1. A newly defined vitreous syndrome following cataract surgery;Irvine;Am J Ophthalmol,1953

2. Cystoid macular edema and papilledema following cataract extraction. A fluorescein fundoscopic and angiographic study;Gass;Arch Ophthalmol,1966

3. Prostacyclin is the major prostaglandin synthesized by bovine retinal capillary pericytes in culture;Hudes;Invest Ophthalmol Vis Sci,1988

4. Pseudophakic cystoid macular edema;Yonekawa;Curr Opin Ophthalmol,2012

5. Difluprednate:An overview;Mithal;Delhi J Ophthalmol,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3